Sorafenib-Based Drug Delivery Systems: Applications and Perspectives

Wang, Lingyun; Chen, M L; Ran, Xueguang; Tang, Hao; Cao, Derong

doi:10.3390/polym15122638

Cited by 8 publications

(2 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such SF nanomedicine systems have been evaluated in co-delivery with biomaterials, chemotherapeutic drugs, imaging agents, and active agents for receptor-mediated binding. They have also expressed great potential in application against various solid tumors, as has been recently reviewed by Wang et al [ 98 ].…”

Section: Nanomedicines For Targeting Tme: Application Of Natural and ...mentioning

confidence: 99%

Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments

Avgoustakis,

Angelopoulou

2024

Pharmaceutics

View full text Add to dashboard Cite

Solid tumors are composed of a highly complex and heterogenic microenvironment, with increasing metabolic status. This environment plays a crucial role in the clinical therapeutic outcome of conventional treatments and innovative antitumor nanomedicines. Scientists have devoted great efforts to conquering the challenges of the tumor microenvironment (TME), in respect of effective drug accumulation and activity at the tumor site. The main focus is to overcome the obstacles of abnormal vasculature, dense stroma, extracellular matrix, hypoxia, and pH gradient acidosis. In this endeavor, nanomedicines that are targeting distinct features of TME have flourished; these aim to increase site specificity and achieve deep tumor penetration. Recently, research efforts have focused on the immune reprograming of TME in order to promote suppression of cancer stem cells and prevention of metastasis. Thereby, several nanomedicine therapeutics which have shown promise in preclinical studies have entered clinical trials or are already in clinical practice. Various novel strategies were employed in preclinical studies and clinical trials. Among them, nanomedicines based on biomaterials show great promise in improving the therapeutic efficacy, reducing side effects, and promoting synergistic activity for TME responsive targeting. In this review, we focused on the targeting mechanisms of nanomedicines in response to the microenvironment of solid tumors. We describe responsive nanomedicines which take advantage of biomaterials’ properties to exploit the features of TME or overcome the obstacles posed by TME. The development of such systems has significantly advanced the application of biomaterials in combinational therapies and in immunotherapies for improved anticancer effectiveness.

show abstract

Section: Nanomedicines For Targeting Tme: Application Of Natural and ...mentioning

confidence: 99%

Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments

Avgoustakis,

Angelopoulou

2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…According to a study, sorafenib appears to have an apparent volume of distribution of 213L. 7 In vitro testing has shown that sorafenib binds to plasma proteins at a rate of 99.5%. The liver plays a significant role in the metabolism of sorafenib, primarily through cytochrome P450 3A4 (CYP3A4) and glucuronidation via uridine diphosphate glucuronyltransferase 1A9 (UGT1A9).…”

Section: Introductionmentioning

confidence: 99%

Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications

Li,

Zhang,

et al. 2024

DDDT

View full text Add to dashboard Cite

Tyrosine kinase inhibitors (TKIs) have been recognized as crucial agents for treating various tumors, and one of their key targets is the intracellular site of the vascular endothelial growth factor receptor (VEGFR). While TKIs have demonstrated their effectiveness in solid tumor patients and increased life expectancy, they can also lead to adverse cardiovascular effects including hypertension, thromboembolism, cardiac ischemia, and left ventricular dysfunction. Among the TKIs, sorafenib was the first approved agent and it exerts anti-tumor effects on hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) by inhibiting angiogenesis and tumor cell proliferation through targeting VEGFR and RAF. Unfortunately, the adverse cardiovascular effects caused by sorafenib not only affect solid tumor patients but also limit its application in curing other diseases. This review explores the mechanisms underlying sorafenib-induced cardiovascular adverse effects, including endothelial dysfunction, mitochondrial dysfunction, endoplasmic reticulum stress, dysregulated autophagy, and ferroptosis. It also discusses potential treatment strategies, such as antioxidants and renin-angiotensin system inhibitors, and highlights the association between sorafenib-induced hypertension and treatment efficacy in cancer patients. Furthermore, emerging research suggests a link between sorafenibinduced glycolysis, drug resistance, and cardiovascular toxicity, necessitating further investigation. Overall, understanding these mechanisms is crucial for optimizing sorafenib therapy and minimizing cardiovascular risks in cancer patients.

show abstract

Investigate Toxicity and Control Size and Morphological of Iron Oxide Nanoparticles Synthesis by PLAIL Method for Industrial, Environmental, and Medical Applications: A Review

Attallah,

Abdulwahid,

Abdulrahman

et al. 2024

Plasmonics

View full text Add to dashboard Cite

Sorafenib-Based Drug Delivery Systems: Applications and Perspectives

Cited by 8 publications

References 93 publications

Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments

Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments

Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications

Investigate Toxicity and Control Size and Morphological of Iron Oxide Nanoparticles Synthesis by PLAIL Method for Industrial, Environmental, and Medical Applications: A Review

Contact Info

Product

Resources

About